Welcome to our dedicated page for Eton Pharmaceuticals news (Ticker: ETON), a resource for investors and traders seeking the latest updates and insights on Eton Pharmaceuticals stock.
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) is a pharmaceutical company focused on developing and commercializing treatments for rare diseases, with particular emphasis on pediatric endocrinology and other rare endocrine and metabolic disorders. Its 2025 press releases highlight a growing portfolio of eight commercial rare disease products, including KHINDIVI, INCRELEX, ALKINDI SPRINKLE, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone, along with late-stage candidates such as ET-600, Amglidia, ET-700, ET-800, and the ZENEO hydrocortisone autoinjector.
The ETON news feed features updates on FDA regulatory milestones, product launches, financial results, and corporate developments. Examples include the U.S. FDA approval of KHINDIVI (hydrocortisone) Oral Solution for pediatric adrenocortical insufficiency, the FDA’s acceptance of the New Drug Application for ET-600 (desmopressin oral solution) with a specified PDUFA target action date, and quarterly earnings reports detailing product sales growth and pipeline investment. The company also reports on its acquisition and relaunch of INCRELEX and GALZIN, and on its inclusion in the Russell 2000 and Russell 3000 indexes.
Investors following ETON news can track how Eton’s commercial portfolio and pipeline evolve through regulatory decisions, label expansion efforts, clinical study plans, and conference participation. Regular press releases also discuss non-GAAP metrics such as Adjusted EBITDA, providing additional context for financial performance. This news page aggregates these company-issued updates so readers can review Eton’s rare disease strategy, key product milestones, and ongoing engagement with the healthcare and investment communities.
Eton Pharmaceuticals (Nasdaq: ETON) has appointed Ingrid Hoos as the new Senior Vice President of Scientific Affairs. Hoos, previously Vice President of Regulatory Affairs at Horizon Therapeutics, brings substantial experience, having overseen the growth of Horizon's FDA-approved products from one to ten during her tenure. Eton CEO Sean Brynjelsen expressed confidence in Hoos's track record with complex product approvals and her potential to contribute to the company’s growth. Eton's focus remains on developing pediatric rare disease products, including its lead product, Alkindi® Sprinkle, currently under FDA review.
Eton Pharmaceuticals (Nasdaq: ETON) has submitted a new drug application (NDA) for its product DS-100, aimed at treating methanol poisoning, which has seen increased cases during the COVID-19 pandemic. The FDA has granted orphan drug designation for DS-100, promising seven years of market exclusivity upon approval. The urgency in the market arises from the recall of over 75 hand sanitizers containing methanol. This NDA marks Eton's second orphan drug submission and fifth overall under FDA review, which also includes other candidates like Alkindi® Sprinkle.
Eton Pharmaceuticals reported its Q1 2020 financial results, noting revenue of $0.1 million from Biorphen sales, impacted by COVID-19. The company acquired U.S. marketing rights for Alkindi Sprinkle and secured $9.8 million in liquidity through a $7.8 million equity raise and credit facility amendments. Eton achieved first-to-file status on its cysteine hydrochloride injection ANDA, allowing potential generic exclusivity. Despite challenges faced during Biorphen's launch, Eton remains optimistic about future product introductions in 2020.
Eton Pharmaceuticals, Inc. (Nasdaq: ETON) has been confirmed as the first filer of an Abbreviated New Drug Application (ANDA) for cysteine hydrochloride injection, referencing Exela Pharma Sciences' Elcys. Eton plans to challenge the validity of Exela's patents in the U.S. Patent & Trademark Office, aiming for a potential product launch in November 2021 if successful. The cysteine injection market is valued at over $50 million annually, and Eton aims to provide a lower-cost alternative to patients.
Eton Pharmaceuticals, Inc. (Nasdaq: ETON) will report its first quarter 2020 financial and operational results on May 14, 2020. A conference call and audio webcast will follow at 4:30 p.m. ET. Investors can access the live webcast on Eton's investor website or by calling specified numbers. Eton specializes in developing innovative drug products, focusing on hospital injectable and pediatric rare disease products. Its initial product, Biorphen, is the only FDA-approved ready-to-use phenylephrine injection, launched in December 2019. The lead pediatric product, Alkindi® Sprinkle, is currently under FDA review.